Form 4: EcoR1 Capital Acquires Pre-Funded Warrants in Zymeworks Inc.

EcoR1 Capital, LLC and related parties acquired pre-funded warrants convertible into common stock of Zymeworks Inc., increasing their potential ownership stake.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., reported the acquisition of pre-funded warrants of Zymeworks Inc.
• The transaction occurred on December 26, 2023.
• A total of 5,086,521 pre-funded warrants were acquired at a price of $0.0001 each.
• These warrants are convertible into an equal number of common stock shares.
• The pre-funded warrants do not have an expiration date.
• The exercise of these warrants is limited to ensure the reporting person's ownership does not exceed 19.99% of the total outstanding shares.
• After the transaction, Qualified Fund owned 4,818,462 of the pre-funded warrants.

Sentiment

Score: 6

Explanation: The document reflects a standard transaction, with no clear positive or negative implications. The acquisition of warrants is a neutral event, with potential for future upside or dilution.

Positives

• The acquisition of pre-funded warrants indicates a potential increase in EcoR1 Capital's stake in Zymeworks Inc.
• The warrants do not have an expiration date, providing flexibility for conversion.
• The conversion of warrants to common stock could provide additional capital to Zymeworks Inc.

Risks

• The exercise of the warrants is capped at 19.99% ownership, which may limit the potential upside for EcoR1 Capital.
• The conversion of warrants to common stock could dilute existing shareholders.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This transaction reflects ongoing investment activity in the biotechnology sector, where companies often utilize warrants as part of their financing strategies.

Comparison to Industry Standards

• Pre-funded warrants are a common financial instrument used in the biotech industry, often as part of private placements or follow-on offerings.
• Similar transactions can be seen with other biotech companies such as Xencor and Immunomedics, where warrants are used to raise capital and provide investors with potential upside.
• The 19.99% ownership cap is a standard clause to avoid triggering certain regulatory thresholds.

Stakeholder Impact

• The transaction could potentially impact shareholders through dilution if the warrants are exercised.
• The increased ownership stake by EcoR1 Capital could signal confidence in Zymeworks Inc.'s future prospects.

Key Dates

Keywords

pre-funded warrants, Zymeworks Inc., EcoR1 Capital, Oleg Nodelman, equity securities, beneficial ownership, investment